1-3 of 3
Michael E. Saunders
Close
Sort by
Journal Articles

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Clinical Trials & Observations
Steven M. Horwitz, Youn H. Kim, Francine Foss, Jasmine M. Zain, Patricia L. Myskowski, Mary Jo Lechowicz, David C. Fisher, Andrei R. Shustov, Nancy L. Bartlett, Maria L. Delioukina, Tony Koutsoukos, Michael E. Saunders, Owen A. O'Connor, Madeleine Duvic
Journal: Blood
Blood (2012) 119 (18): 4115–4122.
https://doi.org/10.1182/blood-2011-11-390211
Published: 2012
Journal Articles

A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies.

Steven M. Horwitz, MD, Julie M. Vose, MD, Ranjana Advani, MD, Kamalesh Sankhala, MD, Swaminathan Padmanabhan, M.D., Paul A. Hamlin, Jr., MD, Andy Chen, MD, PhD, Shannon Wilroy, Jasmine M. Zain, MD, Danielle Wright, Hanna Weissbrot, Maribeth Hohenstein, Pablo J Cagnoni, MD, Michael E Saunders, MD, Owen A. O’Connor, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1570.
https://doi.org/10.1182/blood.V112.11.1570.1570
Published: 2008
Journal Articles

PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B 12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor, MD, PhD, Barbara Pro, M.D., Lauren Pinter-Brown, MD, Leslie Popplewell, MD, Nancy Barlett, MD, Andrei Shustov, MD, Mary Jo Lechowicz, MD, Kerry J Savage, MD, MSc, Bertrand Coiffier, MD, Eric Jacobsen, MD, Pier Luigi Zinzani, MD, Andre Goy, MD, Jasmine Zain, MD, Shannon Wilroy, Molly Patterson, Adam Boyd, Michael E. Saunders, MD, Pablo Cagnoni, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2008) 112 (11): 261.
https://doi.org/10.1182/blood.V112.11.261.261
Published: 2008